Search clinical trials for: Eylea treatment

Total 63300 results

Regeneron Pharmaceuticals

Not yet recruiting

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (SPECTRUM-US)

Visual Impairment | Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD) | Wet Age-related Macular Degeneration (AMD)
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Shin Kong Wu Ho-Su Memorial Hospital

Recruiting

Maximum Treatment Interval With Aflibercept T&E

Neovascular Age-related Macular Degeneration

Taiwan
Benha University

Recruiting

BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Macular Edema

United Arab Emirates
Benha University

Recruiting

BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Macula Lutea Degeneration

United Arab Emirates
Chiang Mai University

Recruiting

Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

Polypoidal Choroidal Vasculopathy

Thailand
Luye Pharma Group Ltd.
Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor)

Not yet recruiting

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

Age Related Macular Degeneration
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

Spain, Korea, Republic of, Czechia, Japan, Singapore, United States, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Portugal, Bulgaria, Latvia, Canada, Hungary, Arge... and more
The University of Hong Kong

Completed

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

Age-Related Macular Degeneration

Hong Kong
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (FIREFLEYE next)

Retinopathy of Prematurity (ROP)

Spain, Korea, Republic of, Singapore, Malaysia, Japan, Taiwan, Bulgaria, Italy, Argentina, Czechia, Greece, Israel, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Sweden, Turkey, United Kingdom, Ukraine, Hungary, Belgium and more
Wake Forest University Health Sciences

Terminated

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Retinal Vein Occlusion

United States
Jaeb Center for Health Research

Completed

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (DRCR AC)

Diabetic Macular Edema

United States
Singapore National Eye Centre
National University Hospital, Singapore; Tan Tock Seng Hospital

Active, not recruiting

Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

Polypoidal Choroidal Vasculopathy

Singapore
McMaster University

Active, not recruiting

Mean Visual Acuity Changes Following Five Injections of Aflibercept

Diabetic Macular Edema

Canada
Ocular Therapeutix, Inc.

Completed

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

Macular Edema | Branch Retinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Bayer
Regeneron Pharmaceuticals

Completed

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye (ARIES)

Macular Degeneration

Spain, Hungary, United Kingdom, Australia, Italy, Canada, France, Germany
Bayer
Regeneron Pharmaceuticals

Completed

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema (APOLLON)

Diabetic Retinopathy

France
Clearside Biomedical, Inc.

Active, not recruiting

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (ODYSSEY)

Neovascular Age-related Macular Degeneration

United States
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
Larkin Community Hospital

Completed

Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy

Adverse Effect of Radiation Therapy
Bayer
Regeneron Pharmaceuticals

Terminated

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment (XPAND)

Neovascular (Wet) Age-related Macular Degeneration

Canada, United Kingdom
Greater Houston Retina Research
Regeneron Pharmaceuticals; Clinical Trials Resource Group, LLC

Active, not recruiting

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial (VOYAGE)

Diabetic Retinopathy

United States, Puerto Rico
Oxurion

Terminated

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema. (INTEGRAL)

Diabetes Mellitus | Diabetic Retinopathy | Diabetic Macular Edema

Latvia, Lithuania, United States, Hungary, Estonia
Bayer

Completed

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina. (ANDROMEDA)

Macular Degeneration

Germany
Jaeb Center for Health Research
Juvenile Diabetes Research Foundation; National Eye Institute (NEI); National... and other collaborators

Completed

Anti-VEGF Treatment for Prevention of PDR/DME

Diabetic Retinopathy | Diabetic Macular Edema

United States, Canada
Bayer
Regeneron Pharmaceuticals

Completed

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (ASTERIA)

Wet Age-related Macular Degeneration

Switzerland
Rishi Singh
Regeneron Pharmaceuticals

Completed

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab (SwapTwo)

Diabetic Retinopathy | Macular Edema

United States
Bayer

Completed

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice (MAIA)

Retinal Disease

Mexico
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Wet Macular Degeneration

Korea, Republic of, United States, China, Argentina, Australia, Denmark, France, Germany, Italy, Poland, Spain, Singapore, Austria, Brazil, Hong Kong, Hungary, Portugal, Russian Federation, Taiwan, Turkey, Bulgaria
University Hospital Inselspital, Berne

Completed

Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen

Age Related Macular Degeneration

Switzerland
Bayer
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease (AURIGA)

Macular Edema

Germany, Italy, Russian Federation, Taiwan, China, Egypt, France, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Diabetic Macular Edema

United States, Japan, Israel, Austria, France, Germany, Hungary, Italy, Mexico, Poland, Slovakia, Spain, Russian Federation, Bulgaria, Turkey, Peru
Neurotech Pharmaceuticals

Terminated

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration

United States, Israel
Janssen Research & Development, LLC

Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Wet Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
The Emmes Company, LLC
National Eye Institute (NEI); University of Wisconsin, Madison; Milton S. Hershey...

Completed

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) (SCORE2)

Central Retinal Vein Occlusion

United States
Bayer

Completed

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Macular Degeneration

Spain, Switzerland, Portugal, France, Canada, United Kingdom, Austria, Slovakia, Germany, Hungary, Italy, Lithuania, Czechia, Poland
Sunnybrook Health Sciences Centre

Unknown

PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept (PRaCTICAL)

Age Related Macular Degeneration | Central Serous Chorioretinopathy | Idiopathic Poplypoidal Choroidal Vasculopathy

Canada
Bayer

Completed

Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece (PERSEUS-GR)

Macular Degeneration | Choroidal Neovascularization

Greece
Jaeb Center for Health Research
National Eye Institute (NEI); National Institutes of Health (NIH); Regeneron...

Completed

Treatment for CI-DME in Eyes With Very Good VA Study (Protocol V)

Diabetic Macular Edema

United States, Canada
Unity Health Toronto

Completed

Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema

Diabetic Macular Edema

Canada
Rabin Medical Center

Terminated

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Corneal Neovascularization

Israel
Greater Houston Retina Research
Regeneron Pharmaceuticals

Completed

Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial

Diabetic Macular Edema

United States
Southeast Retina Center, Georgia

Completed

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab (ROTATED)

Diabetic Macular Edema

United States
Retina-Vitreous Associates Medical Group

Completed

Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema (Endurance3)

Clinically Significant Diabetic Macular Edema
Novartis Pharmaceuticals

Completed

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (SALT)

Neovascular Age-related Macular Degeneration

Germany, Austria, Belgium, Denmark, Switzerland, France, Netherlands, Portugal, Sweden, Norway
Bayer
Regeneron Pharmaceuticals

Completed

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada. (PEGASUS)

Wet Macular Degeneration

Canada
Northern California Retina Vitreous Associates
Regeneron Pharmaceuticals

Completed

The Endurance 1 Trial (Endurance)

Diabetic Macular Edema

Search clinical trials for: Eylea treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations